With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Beach Energy Ltd (ASX: BPT)
According to a note out of Bell Potter, its analysts have retained their buy rating and $1.80 price target on this energy producer's shares. This follows the release of a quarterly update, which was a touch short of its expectations. However, the broker remains positive. Particularly given that Beach Energy is now rolling-off peak capex and into a step-change in production and free cash flow in FY 2025-2026. It also likes that the company has retained a strong balance sheet capable of supporting its progressive dividend policy. Combined with its positive view on Australian east coast gas and LNG markets, and a strong production and earnings growth outlook, it thinks Beach Energy is a share to buy. The Beach Energy share price is trading at $1.61 today.
Regis Resources Ltd (ASX: RRL)
Another note out of Bell Potter reveals that its analysts have retained their buy rating on this gold miner's shares with an improved price target of $2.80. This also follows the release of a quarterly update that was below expectations. Bell Potter notes that this was due to the impacts of severe rainfall events during the quarter. However, despite this, the broker has lifted its earnings estimates materially over the coming years. This is because its increased gold price forecast offsets the weaker-than-expected production. Overall, Bell Potter remains very positive on the company and likes its all-Australian asset portfolio, unhedged exposure to the gold price, and strong free cash flow growth. The Regis Resources share price is fetching $2.21 on Monday.
ResMed Inc. (ASX: RMD)
Analysts at Citi have retained their buy rating on this sleep disorder treatment company's shares with an improved price target of $38.00. Citi was impressed with the company's performance during the third quarter. This was particularly the case with its gross margin, which improved significantly more than Citi was expecting. The good news is that further margin improvements are expected over the next 12 months. In addition, it highlights that it isn't expecting rival Philips to re-enter the market until 2026 and believes that weight loss drugs will help grow awareness of sleep disorders, increasing its addressable market. The ResMed share price is $32.61 this afternoon.
